** Shares of California-based diagnostic firm Bio-Rad BIO.N down 8.25% at $281.10
** Co reports Q4 sales of $667.5 million, missing analysts' estimate of $679.3 million, according to data compiled by LSEG
** Expects 2025 revenue growth of about 1.5% to 3.5% and operating margin of ~13% to 13.5%
** The forecast is mixed, as core growth bracketed expectations, but margins disappointed - Jefferies
** Co says will lay off about 5% of its workforce as a part of its restructuring plan - filing
** Adds will incur between about $45 million and $50 million in costs
** It reported Q4. adj profit of $2.9 vs est. $2.87
** In the last 12 months, the stock has fallen ~15%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。